KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$121000.0.

  • Nektar Therapeutics' Other Non Operating Income fell 83.33% to -$121000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $270000.0, marking a year-over-year increase of 10408.97%. This contributed to the annual value of -$390000.0 for FY2024, which is 9375.7% up from last year.
  • As of Q3 2025, Nektar Therapeutics' Other Non Operating Income stood at -$121000.0, which was down 83.33% from $260000.0 recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Other Non Operating Income high stood at $33.4 million for Q1 2022, and its period low was -$6.3 million during Q4 2023.
  • Its 5-year average for Other Non Operating Income is $1.2 million, with a median of -$120500.0 in 2024.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first crashed by 21436.43% in 2021, then skyrocketed by 219049.41% in 2022.
  • Over the past 5 years, Nektar Therapeutics' Other Non Operating Income (Quarter) stood at -$383000.0 in 2021, then surged by 635.25% to $2.0 million in 2022, then tumbled by 409.61% to -$6.3 million in 2023, then soared by 97.87% to -$135000.0 in 2024, then rose by 10.37% to -$121000.0 in 2025.
  • Its Other Non Operating Income was -$121000.0 in Q3 2025, compared to $260000.0 in Q2 2025 and $266000.0 in Q1 2025.